Is PharmaCyte Biotech Stock a Good Investment?
PharmaCyte Biotech Investment Advice | PMCB |
- Examine PharmaCyte Biotech's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research PharmaCyte Biotech's leadership team and their track record. Good management can help PharmaCyte Biotech navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact PharmaCyte Biotech's business and its evolving consumer preferences.
- Compare PharmaCyte Biotech's performance and market position to its competitors. Analyze how PharmaCyte Biotech is positioned in terms of product offerings, innovation, and market share.
- Check if PharmaCyte Biotech pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about PharmaCyte Biotech's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in PharmaCyte Biotech stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if PharmaCyte Biotech is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine PharmaCyte Biotech Stock
Researching PharmaCyte Biotech's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 13.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.28. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. PharmaCyte Biotech had not issued any dividends in recent years. The entity had 1:1550 split on the 12th of July 2021.
To determine if PharmaCyte Biotech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding PharmaCyte Biotech's research are outlined below:
| PharmaCyte Biotech had very high historical volatility over the last 90 days | |
| PharmaCyte Biotech may become a speculative penny stock | |
| PharmaCyte Biotech has high likelihood to experience some financial distress in the next 2 years | |
| PharmaCyte Biotech currently holds about 82.23 M in cash with (2.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| PharmaCyte Biotech has a poor financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Disposition of tradable shares by Schmieg Martin of PharmaCyte Biotech subject to Rule 16b-3 |
PharmaCyte Biotech Quarterly Liabilities And Stockholders Equity |
|
PharmaCyte Biotech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in PharmaCyte Biotech. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to PharmaCyte Biotech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 31st of January 2024 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact PharmaCyte Biotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises PharmaCyte Biotech's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-03-15 | 2022-01-31 | -0.05 | -0.04 | 0.01 | 20 | ||
2021-12-14 | 2021-10-31 | -0.07 | -0.06 | 0.01 | 14 | ||
2022-12-14 | 2022-10-31 | -0.08 | -0.0914 | -0.0114 | 14 | ||
2022-07-28 | 2022-04-30 | -0.04 | -0.07 | -0.03 | 75 | ||
2023-03-16 | 2023-01-31 | -0.08 | -0.0402 | 0.0398 | 49 | ||
2023-07-31 | 2023-04-30 | -0.09 | -0.0075 | 0.0825 | 91 | ||
2023-12-15 | 2023-10-31 | -0.08 | -0.2576 | -0.1776 | 222 | ||
2023-09-18 | 2023-07-31 | -0.07 | -0.278 | -0.208 | 297 |
Know PharmaCyte Biotech's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as PharmaCyte Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading PharmaCyte Biotech backward and forwards among themselves. PharmaCyte Biotech's institutional investor refers to the entity that pools money to purchase PharmaCyte Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Blackrock Inc | 2024-06-30 | 13.3 K | Tower Research Capital Llc | 2024-06-30 | 7.4 K | Aspire Private Capital, Llc | 2024-09-30 | 800 | Advisor Group Holdings, Inc. | 2024-06-30 | 513 | Royal Bank Of Canada | 2024-06-30 | 261 | Bank Of America Corp | 2024-06-30 | 152 | Planning Capital Management Corp | 2024-09-30 | 100.0 | Redwood Wealth Management Group Llc | 2024-06-30 | 69.0 | Maryland Capital Advisors Inc | 2024-09-30 | 35.0 | K2 Principal Fund Lp | 2024-09-30 | 209.3 K | Vanguard Group Inc | 2024-09-30 | 192.4 K |
PharmaCyte Biotech's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.13 M.Market Cap |
|
PharmaCyte Biotech's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.01 | 0.01 | |
| Return On Capital Employed | (0.12) | (0.13) | |
| Return On Assets | 0.01 | 0.01 | |
| Return On Equity | 0.01 | 0.01 |
Determining PharmaCyte Biotech's profitability involves analyzing its financial statements and using various financial metrics to determine if PharmaCyte Biotech is a good buy. For example, gross profit margin measures PharmaCyte Biotech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of PharmaCyte Biotech's profitability and make more informed investment decisions.
Please note, the presentation of PharmaCyte Biotech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, PharmaCyte Biotech's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of PharmaCyte Biotech's management manipulating its earnings.
Evaluate PharmaCyte Biotech's management efficiency
PharmaCyte Biotech has return on total asset (ROA) of (0.0476) % which means that it has lost $0.0476 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.4788 %, meaning that it created $0.4788 on every $100 dollars invested by stockholders. PharmaCyte Biotech's management efficiency ratios could be used to measure how well PharmaCyte Biotech manages its routine affairs as well as how well it operates its assets and liabilities. At present, PharmaCyte Biotech's Return On Tangible Assets are projected to slightly grow based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.01, whereas Return On Capital Employed is forecasted to decline to (0.13). At present, PharmaCyte Biotech's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 9.9 M, whereas Other Current Assets are forecasted to decline to about 241.3 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.12 | 3.92 | |
| Tangible Book Value Per Share | 3.96 | 7.01 | |
| Enterprise Value Over EBITDA | (10.07) | (10.57) | |
| Price Book Value Ratio | 0.51 | 0.54 | |
| Enterprise Value Multiple | (10.07) | (10.57) | |
| Price Fair Value | 0.51 | 0.54 | |
| Enterprise Value | -29.9 M | -28.4 M |
PharmaCyte Biotech showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta (0.20) |
Basic technical analysis of PharmaCyte Stock
As of the 1st of December, PharmaCyte Biotech holds the Coefficient Of Variation of 1704.99, semi deviation of 4.68, and Risk Adjusted Performance of 0.0534. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of PharmaCyte Biotech, as well as the relationship between them.PharmaCyte Biotech's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific PharmaCyte Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on PharmaCyte Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases PharmaCyte Biotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Schmieg Martin few days ago Disposition of tradable shares by Schmieg Martin of PharmaCyte Biotech subject to Rule 16b-3 | ||
Liquard Thomas over three weeks ago Disposition of 167 shares by Liquard Thomas of PharmaCyte Biotech at 156.0 subject to Rule 16b-3 | ||
Tong Raymond Cf over two months ago Disposition of 334 shares by Tong Raymond Cf of PharmaCyte Biotech at 51.0 subject to Rule 16b-3 | ||
Schmieg Martin over three months ago Disposition of tradable shares by Schmieg Martin of PharmaCyte Biotech subject to Rule 16b-3 | ||
Tong Raymond Cf over three months ago Disposition of 334 shares by Tong Raymond Cf of PharmaCyte Biotech at 51.0 subject to Rule 16b-3 | ||
Michael Abecassis over a year ago Acquisition by Michael Abecassis of 61248 shares of PharmaCyte Biotech subject to Rule 16b-3 |
PharmaCyte Biotech's Outstanding Corporate Bonds
PharmaCyte Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. PharmaCyte Biotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most PharmaCyte bonds can be classified according to their maturity, which is the date when PharmaCyte Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| PHARMACIA P 66 Corp BondUS71713UAW27 | View | |
| PHARMACIA P 675 Corp BondUS71713UAT97 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand PharmaCyte Biotech's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing PharmaCyte Biotech's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0534 | |||
| Market Risk Adjusted Performance | 0.3056 | |||
| Mean Deviation | 3.52 | |||
| Semi Deviation | 4.68 | |||
| Downside Deviation | 5.15 | |||
| Coefficient Of Variation | 1704.99 | |||
| Standard Deviation | 5.18 | |||
| Variance | 26.81 | |||
| Information Ratio | 0.0321 | |||
| Jensen Alpha | 0.1669 | |||
| Total Risk Alpha | (0.57) | |||
| Sortino Ratio | 0.0323 | |||
| Treynor Ratio | 0.2956 | |||
| Maximum Drawdown | 30.25 | |||
| Value At Risk | (6.15) | |||
| Potential Upside | 9.09 | |||
| Downside Variance | 26.47 | |||
| Semi Variance | 21.87 | |||
| Expected Short fall | (4.45) | |||
| Skewness | (0.49) | |||
| Kurtosis | 4.3 |
| Risk Adjusted Performance | 0.0534 | |||
| Market Risk Adjusted Performance | 0.3056 | |||
| Mean Deviation | 3.52 | |||
| Semi Deviation | 4.68 | |||
| Downside Deviation | 5.15 | |||
| Coefficient Of Variation | 1704.99 | |||
| Standard Deviation | 5.18 | |||
| Variance | 26.81 | |||
| Information Ratio | 0.0321 | |||
| Jensen Alpha | 0.1669 | |||
| Total Risk Alpha | (0.57) | |||
| Sortino Ratio | 0.0323 | |||
| Treynor Ratio | 0.2956 | |||
| Maximum Drawdown | 30.25 | |||
| Value At Risk | (6.15) | |||
| Potential Upside | 9.09 | |||
| Downside Variance | 26.47 | |||
| Semi Variance | 21.87 | |||
| Expected Short fall | (4.45) | |||
| Skewness | (0.49) | |||
| Kurtosis | 4.3 |
Consider PharmaCyte Biotech's intraday indicators
PharmaCyte Biotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of PharmaCyte Biotech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
PharmaCyte Biotech time-series forecasting models is one of many PharmaCyte Biotech's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary PharmaCyte Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
PharmaCyte Stock media impact
Far too much social signal, news, headlines, and media speculation about PharmaCyte Biotech that are available to investors today. That information is available publicly through PharmaCyte media outlets and privately through word of mouth or via PharmaCyte internal channels. However, regardless of the origin, that massive amount of PharmaCyte data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of PharmaCyte Biotech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of PharmaCyte Biotech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to PharmaCyte Biotech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive PharmaCyte Biotech alpha.
PharmaCyte Biotech Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards PharmaCyte Biotech can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
When determining whether PharmaCyte Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PharmaCyte Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pharmacyte Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pharmacyte Biotech Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PharmaCyte Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. If investors know PharmaCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PharmaCyte Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.64 | Return On Assets (0.05) | Return On Equity 0.4788 |
The market value of PharmaCyte Biotech is measured differently than its book value, which is the value of PharmaCyte that is recorded on the company's balance sheet. Investors also form their own opinion of PharmaCyte Biotech's value that differs from its market value or its book value, called intrinsic value, which is PharmaCyte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PharmaCyte Biotech's market value can be influenced by many factors that don't directly affect PharmaCyte Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between PharmaCyte Biotech's value and its price, as these two are different measures arrived at by various means. Investors typically determine if PharmaCyte Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PharmaCyte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.